P. Leia Nghiemphu

Department of Neurology, UCLA

Disclosure: Nothing to disclose

Presentation(s):

• QOLP-09 - Impact of glioblastoma (GBM) patients’ clinical and treatment characteristics on caregiver burden and quality of life (QoL)

  Friday, November 22
  2:45 PM – 2:50 PM

• NIMG-54 - Diffusion MRI phenotypes predict overall survival benefit from bevacizumab in recurrent glioblastoma with a large tumor burden: Evidence from clinical practice and a multicenter phase 3 trial

  Friday, November 22
  7:30 PM – 9:30 PM

• QOLP-12 - Evaluation of the UCLA Neuro-Oncology Program psychosocial patient screening form in identifying depression, fatigue, and perceived cognitive function in patients with gliomas

  Friday, November 22
  7:30 PM – 9:30 PM

• NIMG-60 - IDH mutant gliomas with 1p/19q co-deletion are less acidic than non-co-deleted gliomas as measured with pH-weighted amine CEST-MRI and amino acid PET

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-34 - Single agent ONC201 in previously-treated, progressive adult H3 K27M-mutant glioma

  Friday, November 22
  7:30 PM – 9:30 PM

• NCOG-10 - Relationship between cognitive function, mood, and functioning in glioma survivors

  Friday, November 22
  8:18 PM – 8:22 PM

• NIMG-31 - Brain Connectivity Patterns Characterize Cognitive Impairment in Long-Term Survivors of Low-Grade Glioma (LGG) using Resting-State Functional MRI (rs-fMRI)

  Saturday, November 23
  5:00 PM – 7:00 PM